Next 10 |
2024-04-12 11:34:12 ET More on S&P 500 Index: Sticking With The More Optimistic View Where We Stand Sorry Campers, The Fed Is Not Riding To The Rescue Nasdaq, S&P, Dow slip as major banks kick off earnings season Nasdaq, S&P climb, Dow end...
2024-04-11 09:09:06 ET More on Leap Therapeutics Seeking Alpha’s Quant Rating on Leap Therapeutics Historical earnings data for Leap Therapeutics Financial information for Leap Therapeutics Read the full article on Seeking Alpha For further det...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
2024-03-18 10:56:46 ET More on Leap Therapeutics Seeking Alpha’s Quant Rating on Leap Therapeutics Historical earnings data for Leap Therapeutics Financial information for Leap Therapeutics Read the full article on Seeking Alpha For further det...
2024-03-18 07:10:04 ET More on Leap Therapeutics Seeking Alpha’s Quant Rating on Leap Therapeutics Historical earnings data for Leap Therapeutics Financial information for Leap Therapeutics Read the full article on Seeking Alpha For further det...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
2024-01-17 10:00:18 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Health stocks to watch this earnings season as sector poised for resurgence Seeking Al...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncolog...
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients PR Newswire CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX)...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...